
    
      All participants will receive both the investigational (LBN ophthalmic solution 0.024%) and
      placebo treatments, with 1 eye receiving LBN 0.024% and the contralateral eye receiving
      placebo. Each participant will be randomized as to which eye (right or left) will receive LBN
      0.024% versus placebo.

      All participants will undergo a minimum 14-day to maximum 42-day washout period prior to the
      start of study drug administration.
    
  